These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904 [TBL] [Abstract][Full Text] [Related]
24. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Adkins JC; Faulds D Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964 [TBL] [Abstract][Full Text] [Related]
25. [Overviews of fibrate]. Tada N Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141 [No Abstract] [Full Text] [Related]
26. Colesevelam: a review of its use in hypercholesterolemia. Robinson DM; Keating GM Am J Cardiovasc Drugs; 2007; 7(6):453-65. PubMed ID: 18076213 [TBL] [Abstract][Full Text] [Related]
27. Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations. Cardiovasc J Afr; 2011; 22(1):55. PubMed ID: 21298212 [No Abstract] [Full Text] [Related]
28. [Antilipemic agents in combined therapy]. Márk L; Császár A Orv Hetil; 2002 Aug; 143(34):1973-8. PubMed ID: 12422650 [TBL] [Abstract][Full Text] [Related]
30. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states. Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993 [TBL] [Abstract][Full Text] [Related]
32. [Treatment of essential hyperlipidemia with procetofene. Apropos of 100 cases]. Fromantin M; Gautier D; Bon R Sem Hop Ther; 1977; 53(5-6):311-6. PubMed ID: 897691 [No Abstract] [Full Text] [Related]
33. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs. Brown WV Cardiology; 1989; 76 Suppl 1():45-51; discussion 52-4. PubMed ID: 2653623 [TBL] [Abstract][Full Text] [Related]
35. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958 [TBL] [Abstract][Full Text] [Related]
36. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874 [TBL] [Abstract][Full Text] [Related]
37. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M; Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551 [TBL] [Abstract][Full Text] [Related]
38. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia. von Bergmann K; Leiss O Eur J Clin Invest; 1984 Apr; 14(2):150-4. PubMed ID: 6428905 [TBL] [Abstract][Full Text] [Related]
39. [Treatment of high blood cholesterol in patients with coronary heart disease]. Nagai Y; Yamashita S Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049 [No Abstract] [Full Text] [Related]
40. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. Corbelli JC; Bullano MF; Willey VJ; Cziraky MJ; Corbelli ME; Waugh W Am J Cardiol; 2002 Dec; 90(12):1388-91. PubMed ID: 12480052 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]